ESR1 and triple-negative breast carcinoma: Malignant breast cancers, such as triple-negative breast cancer (TNBC), that lack the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) as therapeutic targets exhibit a high proliferation capacity, a high metastatic potential, a high recurrence rate, and a poor prognosis.